AUTHOR=He Kangwei , Li Changjiu , Yuan Hui , Jiang Kang , Deng Gang 

TITLE=Immunological role and prognostic value of SPARCL1 in pan-cancer analysis

JOURNAL=Pathology and Oncology Research

VOLUME=28

YEAR=2022

URL=https://www.por-journal.com/journals/pathology-and-oncology-research/articles/10.3389/pore.2022.1610687

DOI=10.3389/pore.2022.1610687

ISSN=1532-2807

ABSTRACT=<p><bold>Background:</bold> Secreted protein acidic and rich in cysteine-like 1 (SPARCL1) was a kind of extracellular matrix glycoprotein. SPARCL1 was strongly inhibited in most cancers. However, the potential functions of SPARCL1 in the pan-cancer cohort have not been widely studied.</p><p><bold>Methods:</bold> We evaluated the transcriptional level and the prognostic value of SPARCL1 in 33 types of cancer and revealed the relationship between genetic alterations of SPARCL1 and the tumor mutation burden. Meanwhile, we assessed the correlations between SPARCL1 and tumor-infiltrating lymphocytes across cancers.</p><p><bold>Results:</bold> The transcriptional level of SPARCL1 was inhibited in most cancers. Although SPARCL1 was down-regulated in most cancers, SPARCL1 might play a protective or detrimental role in different cancers. We demonstrated that mutation count was elevated in the altered SPARCL1 group in several cancers. Additionally, we found a significant positive correlation between SPARCL1 and macrophage infiltration levels in most cancers. Especially, marker sets of M2 macrophages were strongly related to SPARCL1 in cholangiocarcinoma, colon adenocarcinoma, rectum adenocarcinoma, and pancreatic adenocarcinoma.</p><p><bold>Conclusion:</bold> Our study found that SPARCL1 might work as a biomarker for prognosis and immune infiltration in pan-cancer analysis.</p>